Author: OurCrowd

[Biolojic in Business Wire] New phase 1 dose escalation data show well-tolerated safety profile and anti-tumor activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 3, 2023 |

LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of best-in-class IL-2 therapeutics, today shared new data from its Phase 1/2 clinical trial of AU-007 at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California. The data, from Phase 1 dose escalation cohorts, continue to indicate that AU-007 is well tolerated as a monotherapy treatment or in a combination therapy regimen with low-dose, subcutaneous aldesleukin (recombinant human IL-2). The data also demonstrate early evidence of anti-tumor activity in patients with several solid tumor cancer types. Read...

Read More

[Tabnine in GlobeNewswire] Tabnine appoints Peter Guagenti as president and Chief Marketing Officer

Nov 2, 2023 |

TEL AVIV, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) — Tabnine, the creators of the industry’s first AI-powered assistant for developers, today announced the appointment of Peter Guagenti as President and Chief Marketing Officer (CMO) to lead go-to-market strategy and growth. Guagenti brings decades of leadership excellence at high-growth companies and will help drive Tabnine in its mission to bring generative AI to the entire software development lifecycle (SDLC). As the pioneer in the generative AI coding assistant category, the company currently already serves more than one million developers monthly. Read...

Read More

[ReWalk in GlobeNewsWire] Medicare coverage solidified for ReWalk personal exoskeleton

Nov 2, 2023 |

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced its appreciation to the Centers for Medicare & Medicaid Services (“CMS”) for finalizing the Calendar Year 2024 Home Health Prospective Payment System Rule CMS-1780 (“2024 Home Health Rule”) which solidifies the inclusion of exoskeletons in the Medicare brace benefit category. The final rule was released by CMS on November 1, 2023 and will go into effect beginning on January 1, 2024. Read more...

Read More